Cardio Diagnostics (NASDAQ:CDIO – Get Rating) and Quotient (NASDAQ:QTNT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Insider and Institutional Ownership

77.3% of Cardio Diagnostics shares are owned by institutional investors. 10.5% of Quotient shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cardio Diagnostics and Quotient's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Cardio Diagnostics and Quotient, as provided by MarketBeat.com.

Cardio Diagnostics presently has a consensus price target of $8.00, suggesting a potential upside of 633.94%. Quotient has a consensus price target of $60.00, suggesting a potential upside of ∞. Given Quotient's higher probable upside, analysts plainly believe Quotient is more favorable than Cardio Diagnostics.

Profitability

This table compares Cardio Diagnostics and Quotient's net margins, return on equity and return on assets.

About Cardio Diagnostics

(Get Rating)

Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.

About Quotient

(Get Rating)

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.